- Home
- BBD vs RVMD Comparison
BBD vs RVMD Comparison
Compare BBD & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BBD | RVMD |
|---|---|---|
| Founded | 1943 | 2014 |
| Country | Brazil | United States |
| Employees | 80348 | 883 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3B | 30.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BBD | RVMD |
|---|---|---|
| Price | $3.66 | $183.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 19 |
| Target Price | N/A | ★ $140.84 |
| AVG Volume (30 Days) | ★ 33.3M | 2.1M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $70.86 | N/A |
| Revenue Next Year | $8.33 | $533.02 |
| P/E Ratio | $9.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.73 | $34.00 |
| 52 Week High | $4.30 | $194.56 |
Technical Indicators
Market Signals| Indicator | BBD | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 56.60 | 52.92 |
| Support Level | $3.41 | $176.00 |
| Resistance Level | $3.74 | $193.83 |
| Average True Range (ATR) | 0.08 | 6.99 |
| MACD | 0.01 | -1.33 |
| Stochastic Oscillator | 73.41 | 35.08 |
Price Performance
Historical ComparisonAbout BBD Banco Bradesco Sa
Banco Bradesco is Brazil's second-largest private bank, with about 10%-15% of deposits, and the largest insurance provider in Brazil, with roughly 20%-25% market share. The bank is majority controlled by the Bradesco foundation, a private nonprofit institution focused on education. The bank is also a major asset manager with high-single-digit market share. In 2016, Bradesco acquired the Brazilian operations of HSBC.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.